Teva Gyógyszergyár

What Teva Gyógyszergyár does

Teva Gyógyszergyár Zrt. is the Hungarian operating subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), headquartered at Pallagi út 13, Debrecen, with a 120+ year heritage of pharmaceutical manufacturing in Hungary dating to 1901. The company manufactures generic medicines, specialty pharmaceuticals (respiratory, oncology, migraine, neurodegenerative), biological medicines and biosimilars (including at the Ulm, Germany facility), over-the-counter products, and active pharmaceutical ingredients (APIs) through its wholly-owned TAPI Hungary Industries Kft. subsidiary. Operationally it runs two manufacturing sites in Hungary (Debrecen for APIs and finished products with a High Containment facility, and Sajóbábony for finished products), a Budapest commercial office, and employs 1,001-5,000 people. Within the global Teva platform, the Hungarian entity functions as a strategic manufacturing hub and is part of the world's #1 generic pharmaceutical manufacturer with a 3,500+ product portfolio serving ~200 million patients daily across 60+ countries.

The business model is a B2B/B2B2C prescription and OTC pharmaceutical manufacturer: revenue derives from one-time product sales to wholesalers, pharmacies, hospitals, and healthcare systems, with pricing determined through national healthcare systems, insurance reimbursements, and government negotiations rather than public disclosure. Go-to-market is enterprise field sales targeting healthcare professionals, supported by professional portals (Teva Life) and patient education channels (Life Effects). Distribution is global through pharmacy and hospital channels plus a domestic Hungarian e-commerce platform (tevapatika.hu) for OTC products. Customer segments are diversified across end patients, healthcare professionals, hospitals/pharmacies, and healthcare systems/governments, with no single customer concentration.

R&D capability centers on a generic API development platform (synthetic and fermentation-based) covering oncology, anti-infectives, metabolic diseases, and anesthesiology, supported by an EU/Hungarian-funded GINOP project that produced 6 new generic APIs. The company maintains long-running university partnerships (University of Debrecen) for talent and research, and is expanding into biological medicines with 5 products on market and ~20 programs in development. Recent corporate moves include a June 2025 leadership change (Diderick Turpijn as new Commercial CEO) and deepened strategic cooperation with the University of Debrecen in June 2024.

Name

Teva Gyógyszergyár

Legal name

Teva Gyógyszergyár Zártkörűen Működő Részvénytársaság

Website

https://teva.hu

Company type

Private

Founded year

1901

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Teva Gyógyszergyár Zrt. is the Hungarian subsidiary of NYSE-listed Teva Pharmaceutical Industries, manufacturing generic, specialty, biological, and OTC medicines plus APIs from its Debrecen HQ and Sajóbábony plant, serving ~200 million patients daily across 60+ countries as part of the world's largest generic pharma manufacturer.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD)

Keywords

• Generic pharmaceuticals
• Specialty medicines
• Biological medicines
• Over-the-counter medicines
• Active pharmaceutical ingredients

Headquarters

HQ city

Debrecen

HQ country

Hungary

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Generic Pharmaceuticals: Development and sale of generic medicines that provide affordable alternatives to branded drugs, serving approximately 200 million patients daily globally.
2. Specialty Pharmaceuticals: Specialty medicines focused on respiratory diseases (second largest global supplier on WHO essential medicines list), oncology (top 5 global supplier), migraine, pain, and neurodegenerative diseases.
3. Biological Medicines and Biosimilars: Complex biological medicines derived from living cells, including originator biologics and biosimilar products. Currently 5 biological products on market with approximately 20 programs in various development stages.
4. Over-the-Counter (OTC) Products: Non-prescription medicines available through pharmacies, including products for allergy, cough/cold, fever, blood pressure, blood sugar, cholesterol, and digestive health.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Teva Gyógyszergyár manufactures and supplies generic pharmaceuticals, specialty medicines (respiratory, oncology, migraine, neurodegenerative), biological medicines and biosimilars, over-the-counter consumer health products, and active pharmaceutical ingredients. The Debrecen facility serves as a strategic manufacturing and R&D hub for APIs and finished generics, with a complementary biological drug production plant in Ulm, Germany. The Hungarian entity operates within Teva Pharmaceutical Industries Ltd.'s global network, the world's largest generic pharmaceutical manufacturer serving approximately 200 million patients daily.

Product overview

Teva Gyógyszergyár Zrt. is a subsidiary of Teva Pharmaceutical Industries Ltd., operating as one of the world's largest generic pharmaceutical manufacturers. The company offers a portfolio of over 3,500 different products globally, serving approximately 200 million patients daily. The product portfolio consists of five main categories: (1) Generic Medicines - affordable equivalents of branded drugs; (2) Specialty Medicines - focused on respiratory, oncology, migraine, pain, and neurodegenerative diseases where Teva is ranked second globally for respiratory medicines on WHO's essential medicines list; (3) Biological Medicines - complex therapies from living cells with 5 products on market and ~20 in development; (4) Biosimilar Products - manufactured at Ulm, Germany facility; and (5) Over-the-Counter Products for minor ailments. The company also manufactures Active Pharmaceutical Ingredients (API) through its TAPI division. Teva is the world's leading generic drug manufacturer with over 120 years of operation, and serves patients across major therapeutic areas including asthma, cardiology, mental health, and migraine.

Differentiator

Problem solved

Functional benefit

Brands

• TEVAgy a Hős! (TEVAGY - A Hős): CPR training program developed by Teva employees to teach life-saving resuscitation techniques to laypeople using music and inflatable balls
• Emberarcú Egészségért díj (Human-Faced Health Award)
• Teva Life
• TEVAPatika

Products and services

• Generic Medicines (Generikus gyógyszerek) Generic pharmaceutical products approved by regulators to work the same as original drugs, offered at more affordable prices while maintaining equivalent quality. Served as affordable quality alternatives to brand-name drugs across multiple therapeutic areas, including for approximately 200 million patients globally daily.
• Specialty Medicines (Speciális gyógyszerek) Specialized pharmaceutical products focused on key therapeutic areas including respiratory diseases, oncology, migraine, headaches, pain management, and neurodegenerative diseases. Within this line, Teva is ranked second globally for respiratory medicines on the WHO essential medicines list and top 5 in oncology globally.
• Biological Medicines and Biosimilars (Biológiai gyógyszerek / Biohasonlós készítmények) Complex medicines produced from living cells or organisms that provide advanced treatment options and enable precise, personalized treatments. Currently five biological products are on the market globally with approximately 20 programs in various development phases. Biosimilars are manufactured at the state-of-the-art biological medicines facility in Ulm, Germany.
• Over-the-Counter Products (Vény nélküli gyógyszerek) Non-prescription pharmaceutical products available through the product catalog and pharmacies, including medications for allergies, cold and cough, fever, high blood pressure, blood sugar, cholesterol, and digestive issues. Distributed directly to consumers through the tevapatika.hu e-commerce platform in Hungary and through retail pharmacy channels.
• Active Pharmaceutical Ingredients (Teva API) Active pharmaceutical ingredients manufactured by Teva, with the TAPI (Teva API) division serving as a global supplier of APIs to the pharmaceutical industry worldwide. The Hungarian subsidiary TAPI Hungary Industries Kft. operates the Debrecen active ingredient manufacturing and research center.

Quantifiable outcome

• 200 million patients served daily with Teva medicines
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Debreceni Egyetem (University of Debrecen)coreStrategic or Co-development Partner · 6 June 2024Strategic partnership expanding education collaboration established through two off-site departments: Pharmaceutical Industrial Department (2007) and Industrial Pharmaceutical Manufacturing Department (2011). Includes Teva Scholarship Program and joint research initiatives. Approximately 150 students participated in 2023/2024 academic year, with nearly 50 Teva professionals serving as lecturers.
• Global HOPE (Hematology Oncology Pediatric Excellence)coreStrategic or Co-development PartnerPartnership with non-profit organization providing sustainable approach to cancer and blood disease treatment for children in Africa. Teva provides essential medicines while supporting local healthcare service strengthening. Reached nearly 30,000 children in 2020.
• Direct ReliefcoreStrategic or Co-development PartnerCollaboration with humanitarian medical organization providing healthcare resources to the world's most vulnerable people in disaster and crisis situations.
• Magyar Kardiológusok Társasága (Hungarian Cardiologists Society)minorStrategic or Co-development PartnerProfessional support for the 'TEVAgy a Hős!' (TEVA as Hero) CPR training program, providing medical expertise for resuscitation technique developed by Teva employees.

Scale indicators13 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Perrigo Company: Perrigo is a global consumer self-care and generic pharmaceutical company with a broad OTC and prescription generics portfolio, comparable to Teva Hungary's OTC product lines sold through retail pharmacies.

Emerging players

• Alvotech: Alvotech is a pure-play biosimilars developer and manufacturer with integrated R&D and commercial partnerships across Europe — directly comparable to Teva Hungary's Ulm-based biologics/biosimilars capability and target therapeutic areas.

Direct peers

• Sun Pharmaceutical Industries: Sun Pharma is a major global generic pharmaceutical manufacturer with European commercial operations and a large specialty/branded portfolio — directly comparable in scale, geographic scope, and therapeutic breadth to Teva's network.
• Aurobindo Pharma: Aurobindo is one of the largest Indian-headquartered generic pharmaceutical manufacturers with extensive European presence via Apotex acquisition; comparable product mix in generic FDF and APIs similar to Teva Hungary's TAPI operations.
• Stada Arzneimittel: Stada is a European-focused generic and consumer healthcare company headquartered in Germany, with similar generics-plus-specialty positioning and a strong distribution footprint across Central and Eastern Europe — directly overlapping with Teva Hungary's markets.
• Sandoz: Sandoz is the world's largest generic pharmaceutical company outside Teva and the closest direct peer, similarly offering a broad portfolio of generic and biosimilar medicines distributed globally to hospitals and pharmacies.
• Krka: Krka is a leading Slovenian generic pharmaceutical manufacturer with a broad portfolio of generic FDFs, strong EU distribution, and significant Central/Eastern European market overlap with Teva Hungary.
• Hikma Pharmaceuticals: Hikma is a UK-listed generics and specialty pharmaceutical company with strong hospital-channel positioning in the Middle East, Europe, and the US, mirroring Teva Hungary's hospital-supply business model and injectable/specialty manufacturing capabilities.
• Gedeon Richter: Gedeon Richter is a Hungarian-headquartered pharmaceutical company with generic, branded specialty, and biosimilar operations — the most direct in-country peer with overlapping manufacturing footprint and therapeutic focus (CNS, women's health).
• Viatris: Viatris (formed via the Mylan–Upjohn combination) is a global off-patent medicines company with deep generic, biosimilar, and branded specialty exposure across Europe — directly comparable in scale and product breadth to Teva Hungary's parent network.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/sharer/sharer.php?u=https://www.teva.hu
• LinkedInlinkedin.com/company/actavis-hungary-kft-

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Teva Gyógyszergyár